Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
Lamm
D L
DL
Department of Urology, West Virginia University, Morgantown.
Crissmann
J
J
Blumenstein
B
B
Crawford
E D
ED
Montie
J
J
Scardino
P
P
Grossman
H B
HB
Stanisic
T
T
Smith
J
J
Sullivan
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000628:therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D011897:Random Allocation; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000628:therapy
D001500:BCG Vaccine; D004317:Doxorubicin